3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
5
Carcinoma, Non-Small-Cell Lung
2
Thyroid Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Colorectal Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
16
Cyclophosphamide
8
Nivolumab
7
Gemcitabine
6
Paclitaxel
5
Drug Therapy
5
Docetaxel
5
fludarabine
4
aldesleukin
4
Oxaliplatin
4
Fluorouracil
4
Carboplatin
4
ulixertinib
3
spartalizumab
3
Trastuzumab
3
Radiotherapy
3
Leucovorin
3
Capecitabine
3
trametinib
2
tovorafenib
2
pertuzumab
2
pegilodecakin
2
pazopanib
2
palbociclib
2
osimertinib
2
enzalutamide
2
cemiplimab
2
atezolizumab
2
Taxes
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
naporafenib
×
Dermatologic
×
Clear all
NCT05907304
2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1
Active not recruiting
86 enrolled